WATCH at ₹2,204.90
Earnings recovery is real; H1 cash after capex negative.
Watch: Require cash returns and disciplined valuation.
Home / Research / Laurus Labs Limited
WATCH at ₹2,204.90
Secondary filing-data cross-check; see source ledger
[A,C,D] H1 is six months.
[A,D]
[D] H1 FY27 vs H1 FY26
Earnings recovery is real; H1 cash after capex negative.
Watch: Require cash returns and disciplined valuation.
The CDMO share has risen by 14.3 percentage points from FY25 to H1 FY27. That shift creates a plausible pathway to stronger gross margins and greater customer stickiness. However, there is no publicly disclosed CDMO segment profit margin in the reviewed material. Do not infer its exact margin from the consolidated margin expansion. Generics continues to provide scale and manufacturing discipline. It is a meaningful economic base, not a legacy division to be…
Watch: Track both division mix and consolidated incremental margin. A rise in CDMO share alone is insufficient if working capital or depreciation absorbs the profit.
Small molecules generated roughly 74% of the H1 revenue increase. The Bio business contracted despite the growth narrative surrounding fermentation. This is useful evidence: the current earnings surge does not require every emerging modality to be successful. Quarterly comparisons tell another story. Q2 small-molecule revenue rose about ₹40 crore sequentially, whereas affordable medicines rose about ₹145 crore using the disclosed segment data. The…
Watch: Separate year-on-year structural growth from sequential shipment timing; use rolling half-year performance for underwriting.
The total ARV franchise grew very little year on year in Q2, from ₹733 crore to ₹735 crore. Affordable medicines as a whole grew ₹167 crore, driven primarily by FDF. This implies that non-ARV activities contributed about ₹165 crore of incremental sales on the disclosed rounded figures. The old HIV-centric story is becoming less representative of incremental growth. The ARV franchise still provides meaningful volume and operating scale, but tender concentration,…
Watch: Monitor ARV absolute sales and pricing, non-ARV growth and formulation approvals. Look for profit improvement without relying on unusually favorable tender timing.
16 November 2026 | Q2 FY2027 | NSE LAURUSLABS | Consolidated ₹ crore unless specified.
Key takeaways
The original PDF could not be retrieved in this session; full original-line and page QA remains open.
Reference observed Sage PRO quote ₹2,204.90, 16 November, not independently certified closing price; previous ₹2,424 on 13 November. Approximate 54.03 crore shares imply equity value ₹119,126 crore. H1 owners' PAT ₹809.08 crore implies annualised EPS ₹29.95 and approximately 73.6x P/E.
This is a diagnostic, not a forecast. Earnings growth and a falling stock price do not establish a margin of safety. We require repeat commercial supply, higher cash generation relative to capex and productive incremental capital returns.
The counter-thesis is that the existing manufacturing base and stronger commercial utilisation generate cash sooner than the market expects. The thesis would weaken materially if orders slow while new capacity and working capital continue to absorb capital.
Small-molecule CDMO accounts for almost three-quarters of incremental revenue.
Key takeaways
Quarterly comparisons tell another story. Q2 small-molecule revenue rose about ₹40 crore sequentially, whereas affordable medicines rose about ₹145 crore using the disclosed segment data. The quarter-on-quarter acceleration is therefore not a pure CDMO event. Formulations were especially important. A future earnings miss could occur if the generics contribution normalizes even while CDMO remains healthy.
H1 revenue growth bridge (₹ crore)
Small molecule · 746.0 · Bio decline* · 12.0 · Affordable meds · 276.0
Bio decline is shown as magnitude; contribution is −₹12 crore. Net increase ₹1,010 crore.
Where the growth came from
| Division | H1 FY26 | H1 FY27 | Change |
|---|---|---|---|
| Small molecules | 964 | 1,710 | +746 |
| Bio | 76 | 64 | −12 |
| Affordable medicines | 2,183 | 2,459 | +276 |
| Total | 3,223 | 4,233 | +1,010 |
Investment implication: Separate year-on-year structural growth from sequential shipment timing; use rolling half-year performance for underwriting.
The full Q2 bridge is ₹875 crore small molecules, ₹29 crore Bio, ₹625 crore API and ₹677 crore finished dosage forms (FDF), versus ₹835 crore, ₹35 crore, ₹655 crore and ₹502 crore in Q1, with rounding. In the call, the CFO approximated the increase as ₹40 crore CDMO and ₹160 crore affordable medicines.
These are rounded management comments, not a separate reconciled segment table. The financial lesson is that a small sequential rise in CDMO does not automatically imply slowdown: commercial batches are not delivered in equal quarterly installments.
ARV sales were ₹735 crore in Q2 versus ₹733 crore a year earlier. The wider affordable-medicines portfolio grew principally in formulations. ₹625 crore API and ₹677 crore FDF cover the entire affordable-medicines portfolio, not only ARVs. Monitor tender timing and non-ARV growth separately.
The strategic shift is from a large affordable-medicines base toward a higher-value commercial development and manufacturing franchise. Customer-specific process development, validated routes, quality systems and reliable batch delivery can make repeat orders more durable.
However, qualification is not exclusivity, and clinical-stage projects are not committed commercial revenues. A buyer can dual-source or move volume; supply economics depend on product demand, customer allocation and renewal terms.
Divi's, Neuland, Sai Life and Cohance are useful business-model comparisons, not identical multiples. Compare repeat commercial revenue, client concentration, operating margin, cash generation and incremental capital returns.
Revenue, PBT and owners' profit follow consolidated filing data; company-presentation EBITDA differs from derived operating EBITDA excluding other income. Do not mix definitions.
| ₹ crore except EPS | Q2 FY26 | Q1 FY27 | Q2 FY27 | H1 FY27 |
|---|---|---|---|---|
| Operating revenue | 1,653.47 | 2,026.31 | 2,206.37 | 4,232.68 |
| Other income | 26.96 | 9.18 | 13.01 | 22.19 |
| Derived operating EBITDA, rounded | 403 | 638 | 750 | 1,388 |
| PBT | 269.73 | 481.36 | 591.82 | 1,073.18 |
| Owners' PAT | 194.97 | 367.60 | 441.48 | 809.08 |
| EPS ₹ | 3.61 | 6.81 | 8.17 | 14.98 |
Key takeaways
H1 group PAT around ₹798 crore must be used when comparing consolidated CFO; valuation uses attributable earnings. H1 sales grew 31.3% from ₹3,223.04 crore and company EBITDA was ₹1,406 crore at 33.2% margin. FY26 sales ₹6,812.90 crore, PBT ₹1,181.88 crore. H1 has already achieved roughly 91% of previous annual PBT.
This is real operating recovery but not a justified perpetual incremental margin. Higher D&A, changing product mix and timing can reduce margins. Management indicated EBITDA above 30% and gross margin above 60% under its own definitions; this is not a guaranteed floor.
The FY27 ₹8,800 crore analyst sales assumption requires H2 ₹4,567 crore, approximately 27% above prior-year H2. Treat as a hurdle, not guidance. Compare aggregate commercial shipment schedules and affordability portfolio growth separately. Cash-flow evidence below is critical to assessing quality.
Key takeaways
Two public filing-data reproductions corroborate these rounded figures, and ₹864 crore H1 capex is consistent with the earnings-call capital investment commentary. The original exchange PDF was identified but retrieval failed; individual statutory cash-flow lines and page-image verification remain unresolved.
| ₹ crore | H1 FY26 | H1 FY27 |
|---|---|---|
| Operating cash flow | 1,093 | 805 |
| Physical capital expenditure | 489 | 864 |
| CFO less capex | 604 | -59 |
| Net investing cash flow | -477 | -863 |
| Net financing cash flow | -668 | -30.5 |
| Dividends paid | 43.1 | 64.8 |
CFO/capex fell from 2.24x to 0.93x. Capex rose from 15.2% to 20.4% of half-year revenue; CFO margin fell from 33.9% to 19.0%. These figures do not prove financial distress: negative cash after capex can be rational during a productive expansion. But owner cash cannot be inferred from accounting earnings. The simple cash proxy excludes acquisition, financing and other investment flows and is not fully reconciled FCFE.
| Rounded consolidated balance sheet, ₹ crore | March 26 | September 26 |
|---|---|---|
| Inventory | 2,342 | 2,659 |
| Receivables | 2,155 | 2,242 |
| Trade payables | 1,252 | 1,301 |
| Narrow trade working capital | 3,245 | 3,600 |
| Net block | 3,873 | 3,847 |
| CWIP | 773 | 1,282 |
| Long-term borrowings | 611 | 553 |
| Short-term borrowings | 1,786 | 1,937 |
| Cash and bank | 114 | 28.8 |
| Equity | 5,431 | 6,181 |
| Total assets | 10,511 | 11,514 |
Narrow trade working capital rose ₹355 crore: inventory +₹317 crore, receivables +₹87 crore, payables offset ₹49 crore. This is a balance-sheet bridge, not the exact cash-flow working-capital line. Inventory grew 13.5% while H1 revenue grew 31%; ending-balance inventory days using annualised H1 sales fell to about 115 from 126 on FY26 annual sales, and receivable days to about 97 from 115.
These are proxies, not average-balance DSO or inventory-turn calculations. Absolute working capital can absorb cash even when days improve. Inspect inventory ageing, commercial project timing, advances and collections in the next original filing.
CWIP rose about 66%, to ₹1,282 crore, while net block stayed broadly flat. Net block plus CWIP increased from ₹4,646 crore to ₹5,129 crore. The move into productive assets can raise depreciation before commercial utilisation scales.
Gross borrowings increased about ₹93 crore to ₹2,490 crore; narrow debt less cash/bank increased from ₹2,283 crore to ₹2,461 crore. This is not issuer net debt, which can differ by investments, leases and restrictions.
About 78% of borrowings are short-term; liquidity and refinancing deserve attention. Current assets around ₹5,184 crore and liabilities ₹3,954 crore imply current ratio 1.31x vs 1.33x at March. Inventory and receivables are not cash.
Management retained roughly ₹3,000 crore capex over FY27–FY28 and around ₹1,500 crore annually thereafter depending on opportunities. H1 spend ₹864 crore leaves ₹2,136 crore within the two-year envelope. At ₹8,800 crore annual sales, ₹1,500 crore capex requires a CFO margin above 17% simply to turn the cash proxy positive. At 20% CFO margin, CFO ₹1,760 crore leaves ₹260 crore; at 16%, CFO ₹1,408 crore leaves negative ₹92 crore. These are analyst sensitivities, not guidance.
The incremental-return hurdle: a hypothetical ₹1,000 crore productive investment targeting 15% after-tax return needs ₹150 crore NOPAT or ₹200 crore EBIT at 25% tax. With ₹50–75 crore incremental D&A, EBITDA ₹250–275 crore requires annual sales ₹833–917 crore at 30% EBITDA margin.
Actual project economics require capex timing, maintenance, incremental working capital, yield, capacity qualification and committed customer volumes. Do not convert installed capacity directly to revenue.
A full ROCE based on average operating capital and cash returns is preferable to an asset-only proxy.
Commissioned equipment and commercial supply are different milestones.
SPPS reactor volume: >16,000 L · Reported; not annual output
Largest cited synth.: 2,000 L · Deck capacity specification
Peptide sales target: Not disclosed · No customer or contract value assumed
Key takeaways
Management said validation campaigns could begin in roughly 12–18 months and some of the capacity may generate commercial revenue around 2029. Validation activity may itself occupy substantial capacity. However, utilization in development or validation is not the same as repeat commercial revenue at mature economics. The company has not disclosed committed capacity, project capex or peptide asset turns.
The peptide commercialization clock
| Milestone | Indicative timing | What it means |
|---|---|---|
| SPPS facility | Commissioned by Q2 FY27 | Physical capability exists |
| Validation campaigns | 12–18 months from Oct 2026 | Approx. Oct 2027–Apr 2028; conditional |
| Commercial supplies | Around 2029 for some capacities | Dependent on client/approval |
| Steady-state utilization | Not disclosed | Do not equate with launch |
Investment implication: Model limited pre-commercial income, with material incremental commercial revenue only after verified milestones. Do not assign GLP-1 revenue without confirmed product or contract evidence.
The main analytical trap is converting litres of reactors into revenue without knowing peptide length, synthesis route, cycle duration, yield, purification losses, batch release rate, selling price and customer allocation. Reactor volume is a capacity input, not a sales forecast.
A credible model must distinguish installed, qualified, reserved and commercially utilized capacity. A second trap is assuming that general GLP-1 demand automatically accrues to Laurus. Management expects to play a meaningful role but does not identify an approved GLP-1 supply award in the reviewed evidence.
Treat such participation as optionality.
Resins and oligonucleotides are two very different economic bets.
Peptide resins support SPPS chemistry. Management estimates resin at 10–20% of peptide raw-material costs, depending on the molecule. This is not 10–20% of total manufacturing cost. In-sourcing may improve security of supply, qualify a reliable input chain and reduce procurement margin leakage, but the financial benefit is likely smaller than an unqualified application of the 10–20% range suggests.
Galenvs is a different bet: a Canadian early-stage oligonucleotide and purification capability, approved at a USD 3.5 million pre-money valuation. Management indicated no existing oligo customers at the time of the call. The strategic value lies in building a capability bridge, not immediate earnings. The proposed acquisitions should be treated as announced or approved until closing and financial consolidation are confirmed.
Technology investment map
| Investment | Strategic purpose | Underwriting treatment |
|---|---|---|
| SI & C Resins (52% proposed) | Internal resin / purification inputs | Supply security + cost option |
| Galenvs (60% approved) | Oligo development, purification | Early-stage platform option |
| Existing peptide assets | End-to-end API supply | Core expansion; stage gated |
Investment implication: Track closing, integration, customer wins and internally qualified resins. Give no standalone valuation premium to undisclosed oligo revenue.
Illustration: if raw material is 40% of total manufacturing cost and resins are 15% of raw material cost, resins represent 6% of total cost. A 20% reduction in that resin cost would save 1.2% of total manufacturing cost before qualification and fixed-cost effects.
This is hypothetical, not an estimate of Laurus savings. The more consequential gain could be reliability of supply and the ability to control impurity profiles. For Galenvs, the right first test is paid customer development work and transfer of methods into scalable manufacturing, not consolidated EBITDA contribution.
Key takeaways
The November 15 operating forecast is retained rather than mechanically re-forecasting on a lower price. The current quote implies approximately 73x FY27 base EPS ₹30.3 and 49x FY29 base EPS ₹45. The capex and working-capital hurdle makes the distinction between PAT and owner cash essential.
A ₹260 crore cash proxy in the illustrative 20% CFO margin case on ₹119,126 crore equity value is only about 0.22%; it is not a steady-state yield or fair-value estimate. A full DCF requires normalised cash conversion, project-level capex and terminal reinvestment.
| FY29 analyst scenario | Bear | Base | Bull |
|---|---|---|---|
| Revenue ₹cr | 10,500 | 12,500 | 15,000 |
| EBITDA margin | 29% | 34% | 36% |
| EBITDA ₹cr | 3,045 | 4,250 | 5,400 |
| D&A ₹cr | 850 | 850 | 950 |
| Net interest ₹cr | 220 | 160 | 150 |
| PAT proxy at 25% tax ₹cr | 1,481 | 2,430 | 3,225 |
| EPS ₹ | 27.42 | 44.97 | 59.69 |
| Assumed terminal P/E | 30x | 45x | 55x |
| Indicative price ₹ | 823 | 2,024 | 3,283 |
| Change vs reference | -63% | -8% | +49% |
Bear assumes slower conversion and underutilisation; base continued commercial supply and gradual qualification; bull stronger utilisation and new modalities. All are assumptions, not management guidance, price targets or verified peer multiples.
March 2029 is approximately 2.37 years from the reference. At 45x, preserving the reference price requires EPS ₹49 and profit around ₹2,647 crore. A 12% annual return implies share price about ₹2,882, EPS ₹64.05 at 45x, profit about ₹3,460 crore.
At 34% EBITDA margin, 25% tax, ₹850 crore D&A and ₹160 crore net interest, the revenue hurdle is around ₹16,540 crore. At ₹45 EPS, 35x/45x/55x imply ₹1,575/2,025/2,475. A comparable numeric peer set requires same-date prices, attributable earnings, periods and enterprise debt definitions; not independently reconciled.
Scenario multiples should not be described as peer-derived fair values.
Q3/Q4 FY27: repeat commercial shipments and cash conversion; FY27-end: Bio 4 readiness; mid-2027: KRKA validation start; FY28: peptide validation; FY29: potential commercial peptide milestones. All dates conditional on client and regulatory execution.
Key takeaways
WATCH remains appropriate; no trading signal follows from a lower price alone.
Source-verified research update; the 15 November comprehensive edition remains preserved. Independent full institutional QA, original statutory cash-flow line/page reconciliation, numeric peer valuation and project-level DCF remain outstanding.
[D]
[C,D]
Secondary filing-data cross-check; see source ledger
Secondary filing-data cross-check; see source ledger
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.